Leigh Syndrome Treatment Companies

Latest Leigh Syndrome Treatment Companies Update

• 
  Oct 2023: With the most recent sale of a tranche of shares in Haleon Plc, the consumer health company it spun out last year, GSK Plc has raised £886 million. As per a regulatory notification, the British drug business sold 270 million shares at a price of 328 pence. The price is less than Haleon's closing price by roughly 2.5 percent. Accelerated offers are usually discounted to attract investors to participate in the transaction. Early London trade saw a 2% decline in Haleon's stock. GSK was hardly altered. GSK has said that, following the spinoff, it planned to handle its ownership of Haleon as a financial investment, utilizing the money acquired to bolster its balance sheet and further its objective of enhancing its therapeutic pipeline.

• 
  Jan 2023: A definitive deal has been inked by Zimmer Biomet to purchase Embody, a US-based medical device firm, for $155 million. As part of the agreement, Embody may also get an additional $120 million if other regulatory and business goals are met in the next three years. Zimmer will purchase Embody's whole line of collagen-based biointegrative products as part of the deal. The TAPESTRY biointegrative implant for tendon healing and the TAPESTRYRC arthroscopic implant system for rotator cuff repair are two of these treatments for orthopedic soft tissue injuries. Zimmer Biomet operates in over 25 countries and sells its products in over 100 nations. The US Food and Drug Administration granted Zimmer Biomet 510(k) clearance in November for their Persona OsseoTi Keel Tibia product.

• GSK Plc. (U.K.)


• Bayer AG (Germany)


• Zimmer Biomet (U.S.)


• Stryker Corporation (U.S.)


• Wright Medical Group N.V. (U.S.)


• Integra LifeSciences (U.S.)


• Huazhong Pharmaceutical Co., Ltd (China)


• Zhejiang Tianxin (China)